These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32417881)

  • 21. Implementation of Universal Newborn Screening for Severe Combined Immunodeficiency in Singapore While Continuing Routine Bacille-Calmette-Guerin Vaccination Given at Birth.
    Chan SB; Zhong Y; Lim SCJ; Poh S; Teh KL; Soh JY; Chong CY; Thoon KC; Seng M; Tan ES; Arkachaisri T; Liew WK
    Front Immunol; 2021; 12():794221. PubMed ID: 35046952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children.
    Hesseling AC; Marais BJ; Gie RP; Schaaf HS; Fine PE; Godfrey-Faussett P; Beyers N
    Vaccine; 2007 Jan; 25(1):14-8. PubMed ID: 16959383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population differences in immune responses to Bacille Calmette-Guérin vaccination in infancy.
    Lalor MK; Ben-Smith A; Gorak-Stolinska P; Weir RE; Floyd S; Blitz R; Mvula H; Newport MJ; Branson K; McGrath N; Crampin AC; Fine PE; Dockrell HM
    J Infect Dis; 2009 Mar; 199(6):795-800. PubMed ID: 19434928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.
    Julsgaard M; Christensen LA; Gibson PR; Gearry RB; Fallingborg J; Hvas CL; Bibby BM; Uldbjerg N; Connell WR; Rosella O; Grosen A; Brown SJ; Kjeldsen J; Wildt S; Svenningsen L; Sparrow MP; Walsh A; Connor SJ; Radford-Smith G; Lawrance IC; Andrews JM; Ellard K; Bell SJ
    Gastroenterology; 2016 Jul; 151(1):110-9. PubMed ID: 27063728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of Bacillus Calmette-Guerin vaccine in children born to HIV-1 infected women.
    Thaithumyanon P; Thisyakorn U; Punnahitananda S; Praisuwanna P; Ruxrungtham K
    Southeast Asian J Trop Med Public Health; 2000 Sep; 31(3):482-6. PubMed ID: 11289006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bacillus Calmette-Guerin vaccination in preterm infants.
    Okan F; Karagoz S; Nuhoglu A
    Int J Tuberc Lung Dis; 2006 Dec; 10(12):1337-41. PubMed ID: 17167949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial.
    Cotton MF; Madhi SA; Luabeya AK; Tameris M; Hesseling AC; Shenje J; Schoeman E; Hatherill M; Desai S; Kapse D; Brückner S; Koen A; Jose L; Moultrie A; Bhikha S; Walzl G; Gutschmidt A; Kotze LA; Allies DL; Loxton AG; Shaligram U; Abraham M; Johnstone H; Grode L; Kaufmann SHE; Kulkarni PS
    Lancet Infect Dis; 2022 Oct; 22(10):1472-1483. PubMed ID: 35772447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The immunological effect of revaccination with Bacille Calmette-Guérin vaccine at 19 months of age.
    Andersen A; Roth A; Jensen KJ; Erikstrup C; Lisse IM; Whittle H; Sartono E; Yazdanbakhsh M; Aaby P; Benn CS
    Vaccine; 2013 Apr; 31(17):2137-44. PubMed ID: 23474315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Newborn bacille Calmette-Guérin vaccination induces robust infant interferon-γ-expressing natural killer cell responses to mycobacteria.
    Murphy M; Suliman S; Briel L; Veldtsman H; Khomba N; Africa H; Steyn M; Snyders CI; van Rensburg IC; Walzl G; Chegou NN; Hatherill M; Hanekom WA; Scriba TJ; Nemes E
    Int J Infect Dis; 2023 May; 130 Suppl 1():S52-S62. PubMed ID: 36842756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bacille Calmette Guérin vaccination in pre-term infants.
    Sedaghatian MR; Hashem F; Moshaddeque Hossain M
    Int J Tuberc Lung Dis; 1998 Aug; 2(8):679-82. PubMed ID: 9712284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disseminated bacille Calmette-Guérin disease in Saudi children: clinical profile, microbiology, immunology evaluation and outcome.
    Bukhari E; Alaklobi F; Bakheet H; Alrabiaah A; Alotibi F; Aljobair F; Alshamrani M; Alaki E; Alnahdi F; Alodyani A; Alzamil F
    Eur Rev Med Pharmacol Sci; 2016 Sep; 20(17):3696-702. PubMed ID: 27649674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial.
    Gupta A; Singh P; Aaron L; Montepiedra G; Chipato T; Stranix-Chibanda L; Chanaiwa V; Vhembo T; Mutambanengwe M; Masheto G; Raesi M; Bradford S; Golner A; Costello D; Kulkarni V; Shayo A; Kabugho E; Jean-Phillippe P; Chakhtoura N; Sterling TR; Theron G; Weinberg A;
    Lancet Child Adolesc Health; 2023 Oct; 7(10):708-717. PubMed ID: 37634517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse events following immunisation with bacille Calmette-Guérin vaccination: baseline data to inform monitoring in Australia following introduction of new unregistered BCG vaccine.
    Hendry AJ; Dey A; Beard FH; Khandaker G; Hill R; Macartney KK
    Commun Dis Intell Q Rep; 2016 Dec; 40(4):E470-E474. PubMed ID: 28043221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature.
    Colditz GA; Berkey CS; Mosteller F; Brewer TF; Wilson ME; Burdick E; Fineberg HV
    Pediatrics; 1995 Jul; 96(1 Pt 1):29-35. PubMed ID: 7596718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The association between Bacillus Calmette-Guérin vaccination (1331 SSI) skin reaction and subsequent scar development in infants.
    Birk NM; Nissen TN; Ladekarl M; Zingmark V; Kjærgaard J; Jensen TM; Jensen SK; Thøstesen LM; Kofoed PE; Stensballe LG; Andersen A; Pryds O; Nielsen SD; Benn CS; Jeppesen DL
    BMC Infect Dis; 2017 Aug; 17(1):540. PubMed ID: 28774269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risks of ACTH therapy for West syndrome following BCG vaccination.
    Maki Y; Natsume J; Hori I; Takeuchi T; Negishi Y; Kubota T; Maruyama K; Nakata T; Yamamoto H; Tanaka M; Kawaguchi M; Suzuki T; Shiraki A; Sawamura F; Kidokoro H
    Epilepsy Behav; 2021 May; 118():107924. PubMed ID: 33838621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants.
    Hesseling AC; Cotton MF; Fordham von Reyn C; Graham SM; Gie RP; Hussey GD
    Int J Tuberc Lung Dis; 2008 Dec; 12(12):1376-9. PubMed ID: 19017445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two infants with tuberculid associated with Kawasaki disease.
    Yamada H; Ohta H; Hasegawa S; Azuma Y; Hasegawa M; Kadoya R; Ohbuchi N; Ohnishi Y; Okada S; Hoshide M; Ohga S
    Hum Vaccin Immunother; 2016 Nov; 12(11):2772-2776. PubMed ID: 27435523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses.
    Kagina BM; Tameris MD; Geldenhuys H; Hatherill M; Abel B; Hussey GD; Scriba TJ; Mahomed H; Sadoff JC; Hanekom WA; ; Mansoor N; Hughes J; de Kock M; Whatney W; Africa H; Krohn C; Veldsman A; Kany AL; Douoguih M; Pau MG; Hendriks J; McClainc B; Benko J; Snowden MA; Hokey DA
    Vaccine; 2014 Oct; 32(45):5908-17. PubMed ID: 25218194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contact Investigations With a Single Tuberculin Skin Test on Infants Exposed to Tuberculosis in a Postpartum Care Center During the Neonatal Period.
    Choi SH; Oh CE; Lee J; Cho YY; Kwon Y; Kim J; Lee H; Park SE
    J Korean Med Sci; 2023 Sep; 38(38):e301. PubMed ID: 37750372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.